Takeda’s Paediatric HAE Study Strengthens Real-World Case for Takhzyro
Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The TAHORA study, officially titled “A Multi-national Real-world Outcomes and Treatment Patterns Study of Lanadelumab (Takhzyro) in Paediatric Patients With Hereditary Angioedema,” tracks how well Takeda’s Takhzyro works for children with hereditary angioedema in routine care. It aims to measure time without attacks, real-world use patterns, safety, and health system burden across several countries.
The study looks at lanadelumab, sold as Takhzyro, a preventive drug for hereditary angioedema. It is already approved, and the study does not test a new drug but instead reviews how this existing treatment performs in daily practice in young patients.
This is an observational, non-interventional cohort study that uses past medical records of children who already started long-term Takhzyro treatment. There is no randomization or placebo group, so researchers simply compare outcomes over time in real-world settings rather than in a controlled trial.
The study uses a retrospective design, meaning it looks backwards at data that are already collected in clinics. The primary goal is practical: to see how often attacks happen, how care is delivered, and how safe ongoing use of Takhzyro is for this specific paediatric group.
The study was first submitted in November 2025, marking the formal launch of this real-world evidence effort. The most recent update was posted on February 23, 2026, signaling active study management and ongoing data refinement for investors tracking Takeda’s rare disease portfolio.
The trial is currently recruiting, which means more patient data will be added over time as sites enroll eligible children. Final completion dates are not yet posted, but the primary results will likely emerge after enough follow-up to assess attack-free periods and healthcare use trends.
For investors, this update supports the long-term case for Takhzyro as a cornerstone hereditary angioedema drug in younger patients. Strong real-world data could extend the product’s life cycle, reinforce pricing power, and help defend share against current and future competitors in rare disease treatments.
Competitors in the hereditary angioedema space, including companies with acute or preventive therapies, may feel pressure if Takeda shows clear real-world benefits in children. Positive data could improve sentiment toward TAK by supporting stable or rising HAE revenues and reducing perceived risk around paediatric use.
On the other hand, if the study were to show weaker-than-expected outcomes, it might raise questions on long-term efficacy or resource use in real-world practice. That risk appears limited for now, as the design focuses on understanding patterns rather than testing a risky new approach.
Overall, the active status and fresh update of the TAHORA study underline Takeda’s push to deepen evidence for Takhzyro in paediatric hereditary angioedema, and more details are available on the ClinicalTrials portal as the study continues.
To learn more about TAK’s potential, visit the Takeda Pharmaceutical Company drug pipeline page.
